-+ 0.00%
-+ 0.00%
-+ 0.00%

Quirónsalud-backed VOLGA trial shows improved survival in bladder cancer

PUBT·10/28/2026 09:59:40
Listen to the news
Quirónsalud-backed VOLGA trial shows improved survival in bladder cancer
  • Quirónsalud announced October 28, 2026, that the phase III VOLGA trial improved survival versus surgery alone in muscle-invasive bladder cancer.
  • The durvalumab-enfortumab vedotin regimen benefited patients unable or unwilling to receive cisplatin chemotherapy.
  • Enfortumab vedotin was limited to three preoperative cycles; durvalumab continued after surgery, potentially reducing treatment burden.
  • A second regimen incorporating tremelimumab improved event-free survival but did not demonstrate a statistically significant overall survival benefit.
  • Results were already published in The New England Journal of Medicine and presented at the European Society for Medical Oncology’s 2026 congress.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grupo Hospitalario Quirón SA published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.